Zydus Lifesciences Limited has informed the Exchange about press release dated 03-Oct-2022 titled Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets 3.10.22
Press Release Oct 03 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Mirabegron Extended-Release Tablets. The tablets will be manufactured at Zydus's facility in Ahmedabad, India. This marks a significant milestone as Zydus was among the first applicants to submit a complete application for this drug.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 01 2022
- Press Release Sep 20 2022
- Press Release Sep 16 2022
- Press Release Sep 13 2022
- Press Release Sep 12 2022
Later from Zydus Lifesciences
- Press Release Oct 04 2022
- Press Release Oct 06 2022
- Zydus Lifesciences: General updates
- Press Release Oct 17 2022
- Press Release Oct 22 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences